Stada Arz viewing optimization of Russian operations

23 April 2012

German pharmaceutical producer Stada Arzneimittel is considering optimizing its Russian operations through the sale of two of its four Russian plants and expansion of its local production range, according to a report from europe-health-care-eu.

The company is currently in negotiations with potential buyers among which are Russian and Indian firms about the sale of its Moscow Makiz-Pharma plant and Skopinsky Pharmaceutical Plant, which is located in the Ryazan region, the reports state.

According to Stada plans, the production of some of its drugs will be cheaper in Europe, than in Russia, due to its high taxation, as well as underutilization of some of its local plants. The cost of the deal could reach 130 million euros ($170 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK